PDS Biotechnology Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 03, 2019 08:30 ET
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., July 03, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Corporation Granted U.S. and European Patents for Versamune® - GM-CSF Combination to Overcome Tumor Immune Suppression
June 19, 2019 08:30 ET
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., June 19, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Signs Cooperative Research and Development Agreement with National Cancer Institute to Perform a Phase 2 Clinical Study of PDS0101 in Combination with Other Immune-modulating Agents in Advanced HPV-related Cancers
May 29, 2019 08:30 ET
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology to Present at the 9th Annual LD Micro Invitational
May 28, 2019 08:30 ET
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., May 28, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Announces Publication Supporting Novel Mechanisms of Action of its Proprietary Versamune® Platform in Cancer Immunotherapy
May 15, 2019 08:30 ET
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., May 15, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update
May 14, 2019 16:10 ET
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Appoints Stephen Glover to its Board of Directors
April 08, 2019 08:00 ET
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing novel multifunctional immunotherapeutic...
PDS Biotechnology Completes Merger with Edge Therapeutics
March 18, 2019 06:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”), a clinical-stage immuno-oncology company pioneering the development of novel multifunctional...
Edge Therapeutics Announces Full Year 2018 Financial Results
February 21, 2019 06:15 ET
|
Edge Therapeutics, Inc.
BERKELEY HEIGHTS, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the full-year ended December 31, 2018. Financial Results ...
Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company
November 26, 2018 06:30 ET
|
Edge Therapeutics, Inc.
-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune®, a...